Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study

Gili Regev-Yochay*, Yaniv Lustig, Gili Joseph, Mayan Gilboa, Noam Barda, Ilana Gens, Victoria Indenbaum, Osnat Halpern, Shiri Katz-Likvornik, Tal Levin, Yara Kanaaneh, Keren Asraf, Sharon Amit, Carmit Rubin, Arnona Ziv, Ravit Koren, Michal Mandelboim, Noam H. Tokayer, Lilac Meltzer, Ram DoolmanElla Mendelson, Sharon Alroy-Preis, Yitshak Kreiss

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Identifying COVID-19 correlates of protection and immunity thresholds is important for policy makers and vaccine development. We aimed to identify correlates of protection of BNT162b2 (Pfizer–BioNTech) vaccination against COVID-19. Methods: In this prospective cohort study, households within a radius of 40 km of the Sheba Medical Center in Israel in which a new SARS-CoV-2 infection (defined as the index case) was detected within the previous 24 h were approached between July 25 and Nov 15, 2021. We included adults (aged >18 years) who had received one or two vaccine doses, had an initial negative SARS-CoV-2 PCR and no previous infection reported, and had a valid IgG and neutralising antibody result. The exposure of interest was baseline immune status, including IgG antibody concentration, neutralising antibody titre, and T-cell activation. The outcomes of interest were PCR-positive SARS-CoV-2 infection between day 2 and day 21 of follow-up and intensity of disease symptoms (self-reported via a telephone questionnaire) among participants who had a confirmed infection. Multivariable logistic and ordered logit ordinal regressions were used for the adjusted analysis. To identify immunological thresholds for clinical protection, we estimated the conditional probability of infection and moderate or severe disease for individuals with pre-exposure IgG and neutralising antibody concentrations above each value observed in the study data. Findings: From 16 675 detected index cases in the study region, 5718 household members agreed to participate, 1461 of whom were eligible to be included in our study. 333 (22·8%) of 1461 household members who were not infected with SARS-CoV-2 at baseline were infected within 21 days of follow-up. The baseline (pre-exposure) IgG and neutralising antibodies were higher in participants who remained uninfected than in those who became infected (geometric mean IgG antibody concentration 168·2 binding antibody units [BAU] per mL [95% CI 158·3–178·7] vs 130·5 BAU/mL [118·3–143·8] and geometric mean neutralising antibody titre 197·5 [181·9–214·4] vs 136 ·7 [120·3–155·4]). Increasing IgG and neutralising antibody concentrations were also significantly associated with a reduced probability of increasing disease severity. Odds of infection were significantly reduced each time baseline IgG antibody concentration increased by a factor of ten (odds ratio [OR] 0·43 [95% CI 0·26–0·70]) and each time baseline neutralising antibody titre increased by a factor of two (0·82 [0·74–0·92]). In our cohort, the probability of infection if IgG antibody concentrations were higher than 500 BAU/mL was 11% and the probability of moderate disease severity was 1%; the probability of infection if neutralising antibody titres were above or equal to 1024 was 8% and the probability of moderate disease severity was 2%. T-cell activation rates were not significantly associated with reduced probability of infection (OR 1·04, 95% CI 0·83–1·30). Interpretation: Both IgG and neutralising antibodies are correlates of protection against SARS-CoV-2 infection. Our data suggest that IgG concentrations higher than 500 BAU/mL and neutralising antibody titres of 1024 or more are thresholds for immunological protection from SARS-CoV-2 delta variant infection. Potentially, updated protective thresholds against emerging variants of concern could be calculated, which could support decision makers on administration of new vaccination strategies and on the optimal period between vaccine doses. Funding: Israeli Ministry of Health.

Original languageEnglish
Pages (from-to)e309-e318
JournalThe Lancet Microbe
Volume4
Issue number5
DOIs
StatePublished - May 2023

Funding

FundersFunder number
Nehemia Rubin Excellence in Biomedical Research
TELEM Program of Chaim Sheba Medical Center
Ministry of Health Mexico
Ministry of Health, State of Israel

    Fingerprint

    Dive into the research topics of 'Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study'. Together they form a unique fingerprint.

    Cite this